TScan Therapeutics Announces $30 Million Registered Direct OfferingOn December 26, 2024, TScan Therapeutics, Inc. (NASDAQ: TCRX) entered into a securities purchase agreement with Lynx1 Capital Management LP, an existing shareholder, and an investment
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read TScan Therapeutics’s 8K filing here. TScan Therapeutics Company Profile (Get Free Report) TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients […]
More Stories
Vipshop Holdings Limited (NYSE:VIPS) Receives $17.50 Average PT from Analysts
Shares of Vipshop Holdings Limited (NYSE:VIPS – Get Free Report) have earned a consensus rating of “Hold” from the seven...
Crown Castle (NYSE:CCI) and CubeSmart (NYSE:CUBE) Head to Head Review
CubeSmart (NYSE:CUBE – Get Free Report) and Crown Castle (NYSE:CCI – Get Free Report) are both finance companies, but which...
Contrasting Wynn Macau (OTCMKTS:WYNMY) and Civeo (NYSE:CVEO)
Civeo (NYSE:CVEO – Get Free Report) and Wynn Macau (OTCMKTS:WYNMY – Get Free Report) are both consumer discretionary companies, but...
Analysts Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) PT at $31.67
Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) have earned a consensus rating of “Buy” from the seven...
Reviewing HUYA (NYSE:HUYA) & Nexxen International (NASDAQ:NEXN)
HUYA (NYSE:HUYA – Get Free Report) and Nexxen International (NASDAQ:NEXN – Get Free Report) are both small-cap computer and technology...
Brokerages Set indie Semiconductor, Inc. (NASDAQ:INDI) Price Target at $8.92
indie Semiconductor, Inc. (NASDAQ:INDI – Get Free Report) has been assigned an average rating of “Buy” from the six research...